Psoriasis treatment is aimed at suppressing skin lesions and preventing relapses. Although in the last decade biological therapies have revolutionized the pharmacologic treatment armamentarium for psoriasis, many patients are still inadequately controlled with currently available therapeutics. An advanced understanding of the immunopathogensis of psoriasis has led to development of new drugs that refine existing treatments or target novel molecular and immunologic pathways. Here we review the most promising topical, oral, and injectable psoriasis treatments in the research pipeline, including agents that target cytokines interleukin (IL)-12/23, tumor necrosis factor-α, IL-20, IL-17, IL-22, inhibitors of calcineurin, phosphodiesterase type 4, protein kinase C, Janus kinase, p38 kinase, purine nucleotide phosphorylase, adenosine receptor agonists, and recombinant chaperonin protein. These targeted therapeutics offer the potential for greater clinical efficacy and less toxicity than traditional agents. As the number of treatment options continues to expand, clinicians will have more diverse opportunities to help patients achieve better psoriasis control.
RappS.R., FeldmanS.R., ExumM.L., FleischerA.B.Jr., ReboussinD.M.Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol.1999; 41(3 Part 1): 401–7.
2.
NevittG.J., HutchinsonP.E.Psoriasis in the community: prevalence severity and patients beliefs and attitudes towards the disease. Br J Dermatol.1996; 135: 533–7.
NickoloffB.J., NestleF.O.Recent insights into the immunopathogenesis of psoraisis provide new therapeutic opportunities. J Clin Invest2004; 113: 1664–75.
8.
FitchE., HarperE., SkorchevaI., KurtzS., BlauveltA.Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep.2007; 9(6): 461–7.
9.
KoutrubaN., EmerJ., LebwohlM.Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manage.2010; 6: 123–41.
10.
NogralesK.E., ZabaL.C., Guttman-YasskyE.Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol.2008; 159(5): 1092–102.
11.
WarrenR.B., GriffithsC.E.M.The future of biological therapies. Semin Cutan Med Surg.2010; 29: 63–6.
12.
KimballA.B., GordonK.B., LangleyK.G.Safety and efficacy of ABT- 874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol2008; 144: 200–7.
13.
KimballA.B., ZhongJ., ValdesJ.M.Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48 week results from a phase II trial to severe psoriasis: 48 week results from a phase II trial. J Am Acad Dermatol.2009; 60: AB168.
14.
FraserK.68th Annual Meeting of the American Academy of Dermatology: Miami Beach, Florida, USA, 5–9 March 2010. Am J Clin Dermatol.2010; 11(3): 223–4.
15.
PappK., BissonnetteR., RosophL.Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet.2008; 371: 1337–41.
16.
PappK., WaselN., KunynetzR., LandellsI., AspesletL., HoV.Efficacy of voclosporin (ISA247) for psoriasis treatment: results from the ESSENCE Study. Poster Presentation, 84th Annual Meeting, Canadian Dermatology Association, July 2009.
GottliebA.B., StroberB., KruegerJ.G.An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin.2008; 24(5): 1529–38.
19.
Anti-inflammatory activities of the novel PDE4 inhibitor CC-10004 against human leukocytes in vitro. Celgene Report No. 5042–107 July 1, 2004
20.
Evaluation of anti-arthritic activity in the mAB/LPS-induced experimental murine arthritogenic model. Celgene Report No CLG/002/EM; April 20, 2004
21.
SchaferP.H., PartonA., GandhiA.K.Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol2010; 159(4): 842–55.
NazarianR., WeinbergJ.M.AN2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs.2009; 10(11): 1236–42.
25.
BeutnerK., LathropA., MartiD., GassmuellerJ.AN2728 demonstrates significant efficacy in three phase Ib psoriasis microplaque trials. J Am Acad Dermatol.2009; 60(suppl 3): AB168.
26.
BeutnerK., LathropA., MartiD., ZaneL., ToledoM.AN2728 demonstrates significant safety and efficacy in a phase IIa double-blind trial in plaque type psoriasis. J Am Acad Dermatol.2009; 60(suppl 3): AB168.
27.
Anacor announces positive results from phase 2 psoriasis trial [press release]. Anacor Pharmaceuticals. Available at: http://www.anacor.com/press_release_2009-2-19.php. Published February 19, 2009 Accessed August 10, 2010
28.
Anacor announces phase 2B topline results for AN2728 in psoriasis [press release].Anacor Pharmaceuticals. Available at: http://www.anacor.com/press_release_2010-6-15_2.php. Published June 15 2010. Accessed August 10, 2010
OrtonneJ.P., TassetC., ReichK., SterryW.Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNF alpha monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis preliminary results from a double-blind placebo-controlled trial. J Am Acad Dermatol.2007; 56(2): AB6.
31.
Medical News Today. CIMZIA (certolizumab pegol) demonstrates efficacy in psoriasis patients previously treated with biologics. Available at: http://www.medicalnewstoday.com/articles/72380.php. Published May 29, 2007. Accessed July 15, 2010
MelnikovaI.Psoriasis market. Nat Rev Drug Discov.2009; 8(10): 767–8.
34.
RussellC.B., KerkofK., BiglerJ.Blockade of IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathological abnormalities in human psoriatic skin. J Invest Dermatol2010; 130(S1): S46.
GenoveseM.C., Van den BoschF., RobersonS.A.LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum2010; 62(4): 929–39.
SkvaraH., DawidM., KleynE.The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest.2008; 118(9): 3151–9.
44.
WestK.CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs2009; 10(5): 491–504.
45.
BoyM.G., WangC., WilkinsonB.E.Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol2009; 129: 2299–302.
46.
HarnessJ., ClucasA., KruegerJ., BoyM.Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effects of CP-690,550 in subjects with psoriasis. J Am Acad Dermatol2009; 60(3 suppl): A177.
DuffinK.C., LuchiM., Fidelus-GortR.Novel mechanism for topical treatment of plaque psoriasis – results of a randomized, double blind concentration ranging, vehicle controlled 12 week study with JAK1/JAK 2 inhibitor INCB018424 cream. Presentation, Society for Investigative Dermatology, May 5–8, 2010, Atlanta, GA.
WolkK., WitteE., WarszawskaK.The Th17 cytokine IL-22 induces L-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol.2009; 39: 3570–81.
55.
StenderupK., RosadaC., WorsaaeA., ClausenJ.T., Norman DamT.Interleukin-20 as a target in psoriasis treatment. Ann NY Acad Sci.2007; 1110: 368–81.
WilliamsB., VanagsD., HallS.Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication. Arch Dermatol.2008; 144(5): 683–5.
van EdenW.Xtoll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr Opin Investig Drugs.2009; 9(5): 523–33.
60.
VanagsD., WilliamsB., JohnsonB.Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet.2006; 368(9538): 855–63.
DavidM., AkermanL., ZivM.Treatment of plaque-type psoriasis with oral CF101: data from an exploratory phase 2 clinical trial. Poster Presentation, PSORIASIS 2010 Congress of the Psoriasis International Network, Paris, France, 1–4 July 2010. Available at: http://www.canfite.com/public/Abstracts_posters/Psoriasis%20Abstract%202010.pdf.
64.
SchievenG.L.The biology of p38 kinase: a central role in inflammationCurr Top Med Chem.2005; 5: 921–8.
LawsP.M., YoungH.S.Update of the management of chronic psoriasis new approaches and emerging treatment options. Clin Cosmetic Investig Dermatol.2010; 3: 25–37.
69.
NogralesK.E., ZabaL.C., ShemerA.IL-22 producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol.2009; 123(6): 1244–52.e2.
70.
ZhengY., DanilenkoP., VadezI.Interleukin-22, a Th17 cytokine, mediates IL-23 induced dermal inflammation and acanthosis. Nature2007; 445: 648–51.
71.
KreymborgK., BecherB.IL-22 vs. IL-22: The tissue matters. Open Autoimmun J.2010; 2: 181–6.
